Literature DB >> 6818901

Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography.

K Borner, H Lode, A Elvers.   

Abstract

We describe two methods for the quantitative analysis of apalcillin and its metabolites in serum and urine by reverse-phase high-pressure liquid chromatography (HPLC), a fast isocratic method for the parent drug, and a gradient method that allows the simultaneous assay of two metabolites. Serum was deproteinized with acetonitrile, and urine was diluted with buffer solution. The detection limit was about 0.5 micrograms/ml at a detection wavelength of 254 nm and 1.5 micrograms/ml at 310 nm. Within-batch precision (coefficient of variation) varied from 10.2 to 1.1% for concentrations of 7.8 and 185.3 micrograms/ml of serum, respectively. Recovery rates of 95.1 and 97.7% were found in spiked sera. Results obtained by HPLC correlated well with those from a standard microbiological assay (agar diffusion test); the resulting bivariate regression equation for serum was y-bioassay = 2.5 micrograms/ml + 0.992 X xHPLC, and that for urine was ybioassay = 12.0 micrograms/ml + 1.009 X xHPLC. At a detection wavelength of 315 nm, no interferences were observed in 10 healthy volunteers. Healthy subjects who were given 2 g of apalcillin intravenously excreted 18% of the parent drug within 24 h in the urine. Two inactive compounds were furthermore identified in urine as the isomeric forms of the penicilloic acids. Their excretion within 24 h amounted to 6.9 and 11.2% of the dose.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6818901      PMCID: PMC185698          DOI: 10.1128/AAC.22.6.949

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  2 in total

1.  [Correlation of thromboplastin times in dicumarol treated patients using various preparations of thrombokinase].

Authors:  R Averdunk; K Borner
Journal:  Z Klin Chem Klin Biochem       Date:  1970-05

2.  PC-904, a novel broad-spectrum semisynthetic penicillin with marked antipseudomonal activity: microbiological evaluation.

Authors:  H Noguchi; Y Eda; H Tobiki; T Nakagome; T Komatsu
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

  2 in total
  6 in total

1.  Pharmacokinetics of FCE 22891, a new oral penem.

Authors:  A Saathoff; H Lode; B Hampel; K M Deppermann; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Comparative pharmacokinetics of apalcillin and piperacillin.

Authors:  H Lode; A Elvers; P Koeppe; K Borner
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

4.  Liquid chromatographic assay of ceftizoxime in sera of normal and uremic patients.

Authors:  E M McCormick; R M Echols; T G Rosano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  Is apalcillin nephrotoxic?

Authors:  J P Fillastre; B Moulin; M Godin; J H Frelon
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

6.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.